Phase II Trial of RAD001 in Refractory Colorectal Cancer

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Swedish Medical Center
• Collaborator: Novartis
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens

• Measurable disease

• ECOG 0-2

Exclusion Criteria:

• CNS disease

• Chemotherapy or radiotherapy < 4 weeks prior

• Active bleeding diathesis